Skip to content

Tweetorial #1: BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies

*Activity Post-Survey & Application for CME Credit*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.What are your credentials? (Required.)
2.What is your community of practice?
3.Based on the MAMMOTH & LocoMMotion study, which of following best characterizes the median OS (in months) of patients w/ multiple myeloma refractory to a proteasome inhibitor, IMiD, & CD38-targeting antibody (triple class refractory)?(Required.)
4.Which of the following points should be included when counseling a patient planning to receive teclistamab?(Required.)
5.71 year old female patient diagnosed with IgG MM w/ t(4;14). She received 4 prior tx including daratumumab, lenalidomide, bortezomib, pomalidomide, carfilzomib & isatuximab. She lives 20 miles from cancer center but does not have a caregiver able to travel to cellular therapy center w/ her. Which treatment is best for this patient?(Required.)
6.JD is a 56 year old male diagnosed with IgM MM w/ t(11;14). He received 5 prior regimens & is considered triple class refractory (but has not had carfilzomib or pomalidomide). He is a schoolteacher w/ the summer off but would like to avoid infusions during the school year.  Which treatment is best for JD?(Required.)
EVALUATION FORM
7.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Differentiate pivotal trial results of current and emerging BCMA- directed therapies for RRMM
Determine appropriate therapy based on patient characteristics, efficacy and safety data, risk assessment, and treatment history for patients with RRMM
8.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice.
9.Overall, was this activity fair, balanced and free from commercial bias?
10.If no, please explain:
11.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
12.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
13.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
14.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
15.I certify that I have participated in the continuing education activity entitled, "BCMA-directed T-cell therapies: Driving Home the Differences Between CARs & Bispecific Antibodies" and claim 0.25 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice